|
|
||||||||||
|
J Am Coll Cardiol, 2005; 45:1631-1637, doi:10.1016/j.jacc.2005.02.053 © 2005 by the American College of Cardiology Foundation |





* Department of Medicine II, Johannes Gutenberg-University, Mainz, Germany
Department of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg-University, Mainz, Germany
INSERM U525, Faculté de Médecine Pitié-Salpétrière, Paris, France
Innere Abteilung, Bundeswehrzentralkrankenhaus, Koblenz, Germany
Manuscript received October 30, 2004; revised manuscript received January 25, 2005, accepted February 8, 2005.
* Reprint requests and correspondence: Dr. Renate Schnabel, Johannes Gutenberg-University, Cardiology, Langenbeckstrasse 1, Mainz, Rheinland-Pfalz 55131, Germany. (Email: schnabelr{at}gmx.de).
OBJECTIVES: This prospective study was designed to evaluate the effect of joint determination of two important contrary biomarkershomocysteine and glutathione peroxidase (GPx)-1on cardiovascular risk stratification.
BACKGROUND: Homocysteine plasma levels have been associated with cardiovascular risk. Experimental data suggest that antioxidative GPx-1 activity modulates cardiovascular risk associated with homocysteine.
METHODS: In 643 patients with coronary artery disease, we performed a prospective study to assess the risk of homocysteine plasma levels and GPx-1 activity on long-term cardiovascular risk with a median follow-up of 7.1 years.
RESULTS: Both homocysteine and GPx-1 were among the strongest univariate predictors of future cardiovascular risk, even after adjustment for cardiovascular confounders. Homocysteine levels were significantly elevated in individuals with future cardiovascular events (15.4 vs. 13.4 µmol/l; p < 0.0001); GPx-1 activity was lower (45.3 ± 13.1 vs. 50.2 ± 11.0 U/g hemoglobin; p < 0.0001). In patients with GPx-1 activity below the median value, homocysteine plasma levels above the median were associated with a 3.2-fold (95% confidence interval 1.8 to 5.6; p < 0.0001) increase in cardiovascular risk, whereas it lost its independent risk prediction in individuals with increased antioxidative capacity, as reflected by high GPx-1 activity. In contrast to single determination, combined assessment revealed a significant increase in the area under the curve of cardiovascular risk predictive models from 0.72, including traditional risk factors to 0.75 and also including homocysteine levels and GPx-1 activity.
CONCLUSIONS: Plasma homocysteine levels and GPx-1 activity are complementary in identifying individuals at high cardiovascular risk. Joint determination of both biomarkers provides substantial information on top of classic risk factors in cardiovascular risk assessment.
| ||||||||||
This article has been cited by other articles:
![]() |
S. Musaad and E. N. Haynes Biomarkers of Obesity and Subsequent Cardiovascular Events Epidemiol. Rev., May 10, 2007; (2007) mxm005v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rossi, I. Dalle-Donne, A. Milzani, and D. Giustarini Oxidized Forms of Glutathione in Peripheral Blood as Biomarkers of Oxidative Stress Clin. Chem., July 1, 2006; 52(7): 1406 - 1414. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |